Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacogenetics and Practice: Tailoring Prescribing for Safety and Effectiveness.

Literature DB >> 30555285

Pharmacogenetics and Practice: Tailoring Prescribing for Safety and Effectiveness.

Cathy R Fulton^1,2, Marelize Swart¹, Thomas De Luca¹, Stephanie N Liu¹, Kimberly S Collins¹, Zeruesenay Desta¹, Brandon T Gufford¹, Michael T Eadon¹.

Abstract

Entities: Chemical Disease Gene Mutation Species

Keywords: Advanced practice nurses; INGENIOUS; Pharmacogenetics; Pharmacogenomics

Year: 2018 PMID： 30555285 PMCID： PMC6291225 DOI： 10.1016/j.nurpra.2018.09.021

Source DB: PubMed Journal: J Nurse Pract ISSN： 1555-4155 Impact factor: 0.767

Keyword Cloud
References

× No keyword cloud information.

24 in total

1. Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting.

Authors: Chad A Bousman; Philip Jaksa; Christos Pantelis
Journal: Pharmacogenet Genomics Date: 2017-11 Impact factor: 2.089

2. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade.

Authors: Yuan Ji; Jennifer M Skierka; Joseph H Blommel; Brenda E Moore; Douglas L VanCuyk; Jamie K Bruflat; Lisa M Peterson; Tamra L Veldhuizen; Numrah Fadra; Sandra E Peterson; Susan A Lagerstedt; Laura J Train; Linnea M Baudhuin; Eric W Klee; Matthew J Ferber; Suzette J Bielinski; Pedro J Caraballo; Richard M Weinshilboum; John L Black
Journal: J Mol Diagn Date: 2016-03-03 Impact factor: 5.568

3. Lessons Learned When Introducing Pharmacogenomic Panel Testing into Clinical Practice.

Authors: Marc B Rosenman; Brian Decker; Kenneth D Levy; Ann M Holmes; Victoria M Pratt; Michael T Eadon
Journal: Value Health Date: 2016-10-21 Impact factor: 5.725

4. Routine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommended.

Authors: Adnan M Bhopalwala; Robert A Hong; Zia R Khan; Mona R Valentin; Ramy A Badawi
Journal: Hawaii J Med Public Health Date: 2015-01

5. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.

Authors: J K Hicks; K Sangkuhl; J J Swen; V L Ellingrod; D J Müller; K Shimoda; J R Bishop; E D Kharasch; T C Skaar; A Gaedigk; H M Dunnenberger; T E Klein; K E Caudle; J C Stingl
Journal: Clin Pharmacol Ther Date: 2017-02-13 Impact factor: 6.875

6. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial.

Authors: Víctor Pérez; Ariana Salavert; Jordi Espadaler; Miquel Tuson; Jerónimo Saiz-Ruiz; Cristina Sáez-Navarro; Julio Bobes; Enrique Baca-García; Eduard Vieta; José M Olivares; Roberto Rodriguez-Jimenez; José M Villagrán; Josep Gascón; Josep Cañete-Crespillo; Montse Solé; Pilar A Saiz; Ángela Ibáñez; Javier de Diego-Adeliño; José M Menchón
Journal: BMC Psychiatry Date: 2017-07-14 Impact factor: 3.630

Review 10. Effect of cytochrome P450 2C19*17 allelic variant on cardiovascular and cerebrovascular outcomes in clopidogrel-treated patients: A systematic review and meta-analysis.

Authors: Bo Huang; De-Jun Cui; Ying Ren; Bin Han; Da-Ping Yang; Xun Zhao
Journal: J Res Med Sci Date: 2017-09-26 Impact factor: 1.852